WO2011095995A1 - A process for the preparation of lacosamide - Google Patents

A process for the preparation of lacosamide Download PDF

Info

Publication number
WO2011095995A1
WO2011095995A1 PCT/IN2011/000082 IN2011000082W WO2011095995A1 WO 2011095995 A1 WO2011095995 A1 WO 2011095995A1 IN 2011000082 W IN2011000082 W IN 2011000082W WO 2011095995 A1 WO2011095995 A1 WO 2011095995A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
lacosamide
process according
compound
acid
Prior art date
Application number
PCT/IN2011/000082
Other languages
French (fr)
Inventor
Pulla Reddy Muddasani
Veerababu Madalapu
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Priority to KR1020127023472A priority Critical patent/KR20120128667A/en
Priority to EP11711153.4A priority patent/EP2534128A1/en
Priority to CA2788451A priority patent/CA2788451A1/en
Priority to US13/577,367 priority patent/US8759582B2/en
Publication of WO2011095995A1 publication Critical patent/WO2011095995A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/12—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides

Definitions

  • Present invention relates to an improved and commercial process for the preparation of lacosamide ((R)-2-acetamido-N-benzyl-3-methoxypropanamide) of formula-I
  • Lacosamide is an amino acid derivative having analgesic and anticonvulsant property.
  • Schwarz Pharma (a subsidiary of UCB), under license from Harris FRC, has developed and launched oral (tablet and syrup) lacosamide (Vimpat; formerly known as harkoseride and erlosamide).
  • Lacosamide acts as sodium channel modulator; analgesic; dihydropyrimidinase related protein 2 modulator; anticonvulsant agent.
  • the product is indicated for the adjunctive treatment of partial onset seizures in patients aged at least 17 years.
  • An iv infusion formulation of lacosamide is also available. It was approved by US FDA as an adjunctive therapy for partial-onset seizures in October 2008.
  • Lacosamide is reported for the first time in W09733861 (corresponding US 5773475) by Research Corporation Technologies, USA. It is also published in J. Med. Chem. 1996, 39, 1907-1916. According to this literature, lacosamide can be made in three routes. According to one route (Scheme-I), D-serine is converted to methyl ester and reacted with benzyl amine to get the
  • amino group of D-serine is protected by benzyl chloroformate and reacted with methyl iodide in the presence of silver oxide to get methyl ester of O-methyl derivative (Scheme-Ill).
  • the ester is hydrolyzed and converted to benzylamide via mixed anhydride technique.
  • the amino group protection is removed by hydrogenation and converted to lacosamide by acetylation using acetic anhydride.
  • Overall yield of lacosamide by this route is 43.6%. This route is not commercially viable as it requires column chromatography in the amide intermediate (IV) isolation stage.
  • N-protected D-serine is reacted with methyl iodide to get O-methyl methyl ester compound of formula-VII.
  • Compound of formula- VII is hydrogenated, N-acetylated, ester group hydrolyzed, and amidated with benzyl amine to get lacosamide of formula-I.
  • Overall yield of lacosamide by this route is 37.3%.
  • Lacosamide produced by this method contained about 15% of chiral impurity. Therefore, this route is not viable on commercial scale.
  • N-protected D- serine is reacted with benzylamine to get the amide of formula-XIV.
  • XXIV X A process for the preparation of lacosamide is also disclosed in IPCOM # 000181080D.
  • phthalimido group is selected for N-protection of D-serine (Scheme- VIII).
  • the main objective of the present invention is to provide an improved process for the preparation of lacosamide, which is commercially applicable.
  • Another objective of the present invention is to provide an improved process for the preparation of lacosamide avoiding the formation of liquid intermediates at late stage of the synthesis.
  • process of the present invention provides an improved process for the preparation of lacosamide of formula-I,
  • D-serine is reacted with Boc anhydride in aqueous alkali medium at 0-30°C.
  • process for the N-protection of D-serine or any other amino acid with Boc anhydride is performed in water medium along with water soluble solvents such as t-butanol, THF, dioxane, methanol, acetonitrile, dimethylformamide, etc.
  • water soluble solvents such as t-butanol, THF, dioxane, methanol, acetonitrile, dimethylformamide, etc.
  • no organic solvent is used for the preparation of N-Boc-D- serine.
  • Amount of base used is 2-3 equivalents to D-serine.
  • Amount of Boc anhydride used in this reaction is 1.0-1.6 equivalents to D-serine.
  • the base used in this step is selected from sodium or potassium hydroxide, carbonate, bicarbonate, etc., preferably sodium or potassium hydroxide, more preferably sodium hydroxide. Concentration of base used is 3-6 M in water.
  • Process of the present invention does not require any organic solvent for conversion o'f D-serine to N-Boc D-serine. Also, the same reaction mass can be used for methylation using dimethyl sulphate as methylating agent. In methylation step no phase transfer catalyst is required as mentioned in the prior art (WO2006037574). Also, no organic solvent is required.
  • Compound of formula-XVII formed in the reaction can be isolated after neutralization and extraction into an organic solvent. Overall yield of compound of formula-XVII from D-serine is more than 90%.
  • Compound of formula-XXXII is acetylated using acetic anhydride or acetyl chloride in an organic solvent in the presence or absence of a catalyst such as 4- dimethylaminopyridine (DMAP) to get compound of formula-XIII.
  • Temperature of the reaction can be in the range of 0-40°C, preferably 20-30°C.
  • Preferred acylating agent is acetic anhydride.
  • Preferred solvent is ethyl acetate, toluene, methylene chloride, etc.
  • the product formed in the reaction is isolated by simply distilling of solvent. Traces of acetic anhydride present in the mass can be removed by stripping with methanol. Product is formed in quantitative yield. ⁇ ' ' ⁇ ⁇
  • Compound of Formula-XIII is reacted with an .alkyl chloro formate such as methyl chloroformate, ethyl chloroformate. isobutyl chloroformate in the presence of a tertiary amine such as N-methylmorpholine, triethylamine, diisopropylethylamine at -40 to 20°C to get a mixed anhydride of the formate.
  • a tertiary amine such as N-methylmorpholine, triethylamine, diisopropylethylamine at -40 to 20°C to get a mixed anhydride of the formate.
  • the in situ formed formate mixed anhydride is reacted with benzylamine in the presence of same base at -40°C to 25 °C to get lacosamide of formula-I.
  • Solvent of the reaction is toluene, ethyl acetate, cyclohexane, heptane, etc., preferably toluene or ethyl acetate.
  • the crude product obtained from the reaction mass can be recrystallized from a number of organic solvents such as ethyl acetate, toluene, methyl isobutyl ketone, acetone, etc. to get pharmaceutically acceptable grade lacosamide.
  • Overall yield of lacosamide from compound of formula-XIII is more than 70%.
  • Lacosamide produced by the process of present invention contains less than 0.1 % of chiral isomer. It is suitable for formulations in treatment of central nervous system disorders.
  • N-Boc-O-methyl-D-serine Into a 2L, four-necked RB flask was charged 90 ml of water and 40 g of sodium hydroxide. D-Serine is added to the solution at 20-25 °C. Boc anhydride (150 g) is slowly added to the reaction mass keeping the temperature below 20°C. The reaction mass was allowed to reach 25-30°C and maintained for 16 h. TLC of the reaction mass showed the presence of D-serine content at ⁇ 1.0% level.
  • reaction mass is cooled to 0-5°C and started the simultaneous addition of aqueous sodium hydroxide (104 g of sodium hydroxide dissolved in 100 ml of water) and dimethyl sulphate (300 g) through addition funnels keeping the temperature below 5°C.
  • the reaction mass was maintained at same temperature till the completion of reaction.
  • the reaction mass is diluted with water and extracted the product into diisopropyl ether.
  • Aqueous layer is neutralized with citric acid to get ⁇ 3.5 pH.
  • the reaction mass is extracted with diisopropyl ether and distilled of solvent to get 87 g of title compound as an oil.
  • N-acetyl-O-iriethyl-D-serine Into a 1L, four-necked, RB flask was charged 500 ml of ethyl acetate and 50 g of O-methyl-D-serine trifluoroacetate salt. The reaction mass was cooled to 0-5°C and added acetic anhydride (43.8 g). The reaction mass was stirred at 25°C for 20 h and cooled to 0-5°C. After stirring for lh reaction mass was filtered and washed the wet cake with 50 ml of ethyl acetate. The wet solid was dried at 60°C to get 40g of N-acetyl-O-methyl-D-serine as white crystalline solid.
  • Present process avoids the usage of phase transfer catalysts in methylation step. 3.
  • Present process utilizes high purity crystalline solids such as compound of fOrmulae-XXXII and XII for making lacosamide.
  • Lacosamide produced by the process of present invention is free of chiral impurity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Present invention relates to an improved and commercial process for the preparation of lacosamide ((R)-2-acetamido-N-benzyl-3-methoxypropanamide) of formula (I). Present process utilizes high purity crystalline solids of formulae (XXXII) and (XIII) as key intermediates. Lacosamide is indicated for the adjunctive treatment of partial onset seizures in patients aged at least 17 years.

Description

A PROCESS FOR THE PREPARATION OF LACOSAMIDE
FIELD OF INVENTION
Present invention relates to an improved and commercial process for the preparation of lacosamide ((R)-2-acetamido-N-benzyl-3-methoxypropanamide) of formula-I
Figure imgf000002_0001
Lacosamide is an amino acid derivative having analgesic and anticonvulsant property. Schwarz Pharma (a subsidiary of UCB), under license from Harris FRC, has developed and launched oral (tablet and syrup) lacosamide (Vimpat; formerly known as harkoseride and erlosamide). Lacosamide acts as sodium channel modulator; analgesic; dihydropyrimidinase related protein 2 modulator; anticonvulsant agent. The product is indicated for the adjunctive treatment of partial onset seizures in patients aged at least 17 years. An iv infusion formulation of lacosamide is also available. It was approved by US FDA as an adjunctive therapy for partial-onset seizures in October 2008.
BACKGROUND OF INVENTION
Lacosamide is reported for the first time in W09733861 (corresponding US 5773475) by Research Corporation Technologies, USA. It is also published in J. Med. Chem. 1996, 39, 1907-1916. According to this literature, lacosamide can be made in three routes. According to one route (Scheme-I), D-serine is converted to methyl ester and reacted with benzyl amine to get the
Figure imgf000002_0002
D -S e rin e I I I II
P h 1 . R e.crysta lliza tio n
Figure imgf000002_0003
2 . e th yla tio n
IV I
Scheme-I corresponding benzylamide. This intermediate is reacted with acetic anhydride to get the N-acetyl derivative. Methylation using methyl iodide in the presence of silver (I) oxide gave lacosamide. Overall yield of lacosamide by this route is 6.9%. This route is not commercially viable due to low yield and usage of costly reagent like silver oxide.
According to another route (Scheme-II) D-serine is reacted with acetic anhydride to get the corresponding N-acetyl derivative. This intermediate is reacted with benzylamine to get the corresponding benzylamide derivative which on methylation using methyl iodide and silver (I) oxide gave lacosamide. Overall yield of lacosamide by this route is 28.7%. This route is not commercially viable as it requires column chromatography in the amide intermediate (IV) isolation stage.
Figure imgf000003_0001
D-Serine V IV I
Scheme-II
According to one more route described in the above reference, amino group of D-serine is protected by benzyl chloroformate and reacted with methyl iodide in the presence of silver oxide to get methyl ester of O-methyl derivative (Scheme-Ill). The ester is hydrolyzed and converted to benzylamide via mixed anhydride technique. The amino group protection is removed by hydrogenation and converted to lacosamide by acetylation using acetic anhydride. Overall yield of lacosamide by this route is 43.6%. This route is not commercially viable as it requires column chromatography in the amide intermediate (IV) isolation stage.
Figure imgf000003_0002
Slight variations of the process discussed in above Scheme-Ill are disclosed in
Figure imgf000004_0001
XII XIII I
Scheme-IV
According to one variation (A) in this report N-protected D-serine is reacted with methyl iodide to get O-methyl methyl ester compound of formula-VII. Compound of formula- VII is hydrogenated, N-acetylated, ester group hydrolyzed, and amidated with benzyl amine to get lacosamide of formula-I. Overall yield of lacosamide by this route is 37.3%. Lacosamide produced by this method contained about 15% of chiral impurity. Therefore, this route is not viable on commercial scale. In the second variation (B), N-protected D- serine is reacted with benzylamine to get the amide of formula-XIV. Compound of formula-XIV is hydrogenated, N-acetylated, and O-methylated to get lacosamide of formula-I. Overall yield of lacosamide by this route is 43.7%. This route is not commercially viable as it requires chromatography technique for purifications intermediate of formula-XIV. Lacosamide produced by this method contained no chiral impurity. In the third variation (C), compound of formula-XIV is O-methylated, hydrogenated and N-acetylated to get lacosamide of formula-I. Overall yield of lacosamide by this route is 50.8%. Lacosamide produced by this method contained no chiral impurity. This route is not viable on commercial scale as it requires chromatographic technique for purifications of some of the intermediates involved in the process.
An improved process for the preparation of lacosamide is disclosed in WO2006037574 (equivalent US application No. 2008027137). In this disclosed method D-serine is N- protected with Boc group and O-methylated with methylating agents such as methyl iodide and dimethyl sulphate (Scheme-V). The resultant compound of formula-XVII is reacted with benzylarhine to get the corresponding amide of formula-XVIII. N- deprotection of Boc group from compound of formula-XVIII gave the compound of formula-X which on acetylation gave lacosamide of formula-I. Overall yield of' lacosamide by this route is 43.7%. This route is not commercially viable as some of the i
Figure imgf000005_0001
Scheme-V
A novel process for the preparation of lacosamide is also disclosed in Bioorg. Med. Chem. 2008, 16, 8968-8975 starting from methyl ester of D-serine -(Scheme- VI). Methyl ester of D-serine is converted to an aziridine intermediate of formula-XIX. N-acetylation of compound of formula-XIX followed by ring opening with methanol in the presence of an acid catalyst gave the compound of formula-XII. Ester hydrolysis of compound of formula-XII followed by reaction with benzylamine using DMTMM (4-(4,6-dimethoxy- l,3,5-triazin-2-yl)-4-methylmorpholinium chloride) gave lacosamide of formula-I. This route is not commercially viable as it requires usage of costly reagents like DTPP, DMTMM, lithium hydroxide, and BF3 etherate.
Figure imgf000006_0001
D-Serine Me ester XIX XX XII
Figure imgf000006_0002
XIII
DTPP: Diethoxytriphenylphosphorane
Scheme-VI
A process for the preparation of lacosamide is disclosed in US patent application No. 20090143472 using trityl group for N-protection of D-serine (Scheme-VII). In this process costly and polluting reagents like trimethylsilyl chloride, trityl chloride, hexamethyldisilazine, sodium hydride, methyl iodide were used. Therefore, this route is not commercially viable.
XXIV X
Figure imgf000006_0003
A process for the preparation of lacosamide is also disclosed in IPCOM # 000181080D. In this disclosure phthalimido group is selected for N-protection of D-serine (Scheme- VIII).
Figure imgf000007_0001
Scheme-VIII
Keeping in view of the difficulties in commercialization of the above-mentioned processes for the preparation of lacosamide, we aimed to develop a simple and economical process for commercial production of lacosamide.
We observed that a promising approach for a process for the preparation of lacosamide would be to (a) avoid the usage of costly and difficult to handle reagents; (b) avoid usage of chromatography technique; (c) and avoid the preparation of liquid intermediates at late stage of the synthesis.
Accordingly, the main objective of the present invention is to provide an improved process for the preparation of lacosamide, which is commercially applicable. Another objective of the present invention is to provide an improved process for the preparation of lacosamide avoiding the formation of liquid intermediates at late stage of the synthesis. PROCESS OF THE PRESENT INVENTION
The present invention has been developed based on our finding that the N-deprotection of compound of formula-XVII would give (R)-O-methylserine. Acetylation of this intermediate would give (R)-O-methyl-N-acetylserine. Amidation of this intermediate with benzylamine would give lacosamide of formula-!. From the literature search it is found that (R)-O-me'thylserine and (R)-O-methyl-N-acetylserine are crystalline solids. Process of the present invention is as given in Scheme-IX.
Figure imgf000008_0001
Scheme-IX
Processes disclosed in the prior art (CN101591300A) for the preparation of compound of formula-XXXII require costly reagents like sodium hydride, methyl iodide, and uses environmentally unfriendly solvents such as N,N-dimethylformamide or dimethyl sulfoxide.
Accordingly, process of the present invention provides an improved process for the preparation of lacosamide of formula-I,
Figure imgf000008_0002
which comprises: reaction of D-serine with Boc anhydride in the presence of a base in aqueous medium to get N-Boc derivative of formula-XVI,
Figure imgf000009_0001
XVI
reaction of N-Boc derivative of formula-XVI with dimethyl sulphate in the presence of a base in aqueous medium to get the compound of formula-XVII,
Figure imgf000009_0002
XVII
reaction of compound of formula-XVII with trifluoroacetic acid to get the novel trifluoroacetate salt of (R) O-methylserine of formula-XXXII,
Figure imgf000009_0003
XII
acetylation of compound of formula-XXXII "with acetic anhydride or acetyl chloride to get the compound of formula-XIII,
Figure imgf000009_0004
XIII
amidation of compound of formula-XIII with benzylamine via mixed anhydride method to get crude lacosamide of formula^,
Figure imgf000009_0005
I 6. recrystallization of crude lacosamide from a solvent to get pharmaceutically acceptable grade lacosamide.
In a preferred embodiment of the present invention D-serine is reacted with Boc anhydride in aqueous alkali medium at 0-30°C. In the prior art (Organic Syntheses, Coll. Vol. 7, page 70 (1990)) process for the N-protection of D-serine or any other amino acid with Boc anhydride is performed in water medium along with water soluble solvents such as t-butanol, THF, dioxane, methanol, acetonitrile, dimethylformamide, etc. In the process of present invention no organic solvent is used for the preparation of N-Boc-D- serine. Amount of base used is 2-3 equivalents to D-serine. Amount of Boc anhydride used in this reaction is 1.0-1.6 equivalents to D-serine. The base used in this step is selected from sodium or potassium hydroxide, carbonate, bicarbonate, etc., preferably sodium or potassium hydroxide, more preferably sodium hydroxide. Concentration of base used is 3-6 M in water. Process of the present invention does not require any organic solvent for conversion o'f D-serine to N-Boc D-serine. Also, the same reaction mass can be used for methylation using dimethyl sulphate as methylating agent. In methylation step no phase transfer catalyst is required as mentioned in the prior art (WO2006037574). Also, no organic solvent is required. Compound of formula-XVII formed in the reaction can be isolated after neutralization and extraction into an organic solvent. Overall yield of compound of formula-XVII from D-serine is more than 90%.
Compound of formula-XVII is hydrolyzed with trifluoroacetic acid at 0-30°C to get O- methyl-D-serine trifluoroacetate of formula-XXXIL The reaction can be done with or without an organic solvent. Product formed in the reaction mass is isolated by direct filtration of reaction mass or after partial concentration. Yield of O-methyl D-serine trifluoroacetate is quantitative.
Compound of formula-XXXII is acetylated using acetic anhydride or acetyl chloride in an organic solvent in the presence or absence of a catalyst such as 4- dimethylaminopyridine (DMAP) to get compound of formula-XIII. Temperature of the reaction can be in the range of 0-40°C, preferably 20-30°C. Preferred acylating agent is acetic anhydride. Preferred solvent is ethyl acetate, toluene, methylene chloride, etc. The product formed in the reaction is isolated by simply distilling of solvent. Traces of acetic anhydride present in the mass can be removed by stripping with methanol. Product is formed in quantitative yield. ■ ' ' ■ <
Compound of Formula-XIII is reacted with an .alkyl chloro formate such as methyl chloroformate, ethyl chloroformate. isobutyl chloroformate in the presence of a tertiary amine such as N-methylmorpholine, triethylamine, diisopropylethylamine at -40 to 20°C to get a mixed anhydride of the formate. The in situ formed formate mixed anhydride is reacted with benzylamine in the presence of same base at -40°C to 25 °C to get lacosamide of formula-I. Solvent of the reaction is toluene, ethyl acetate, cyclohexane, heptane, etc., preferably toluene or ethyl acetate. The crude product obtained from the reaction mass can be recrystallized from a number of organic solvents such as ethyl acetate, toluene, methyl isobutyl ketone, acetone, etc. to get pharmaceutically acceptable grade lacosamide. Overall yield of lacosamide from compound of formula-XIII is more than 70%.
Lacosamide produced by the process of present invention contains less than 0.1 % of chiral isomer. It is suitable for formulations in treatment of central nervous system disorders.
The details of the invention are given in the Examples given below which are provided to illustrate the invention only and therefore should not be construed to limit the scope of the present invention.
EXAMPLES
Example 1:
Preparation of N-Boc-O-methyl-D-serine: Into a 2L, four-necked RB flask was charged 90 ml of water and 40 g of sodium hydroxide. D-Serine is added to the solution at 20-25 °C. Boc anhydride (150 g) is slowly added to the reaction mass keeping the temperature below 20°C. The reaction mass was allowed to reach 25-30°C and maintained for 16 h. TLC of the reaction mass showed the presence of D-serine content at <1.0% level. The reaction mass is cooled to 0-5°C and started the simultaneous addition of aqueous sodium hydroxide (104 g of sodium hydroxide dissolved in 100 ml of water) and dimethyl sulphate (300 g) through addition funnels keeping the temperature below 5°C. The reaction mass was maintained at same temperature till the completion of reaction. The reaction mass is diluted with water and extracted the product into diisopropyl ether. Aqueous layer is neutralized with citric acid to get < 3.5 pH. The reaction mass is extracted with diisopropyl ether and distilled of solvent to get 87 g of title compound as an oil.
Example 2:
Preparation of O-methyl-D-serine trifluoroacetate salt: Into a 1L, four-necked, RB flask was charged 330 ml of diisopropyl ether and 78 g of N-Boc-O-methyl-D-serine. The reaction mass was cooled to <5°C and added 400 g of trifluoroacetic acid. The reaction temperature was allowed to reach 25°C and maintained for 20h. Solvent and excess trifluoroacetic acid was distilled of from the reaction mass under vacuum at 60°C. The residue was crystallized from ethyl acetate/diisopropyl ether and filtered to get 50g of O-methyl-D-serine trifluoroacetate salt as white crystalline solid. M. R.: 228-230°C. IR (KBr): 3415, 3133, 2980, 2932, 1726, 1680, 1646, 1560, 1425, 1366, 1256, 1210, 1 184, 1 125, 964, 842, 798, 726 and 514 cm'1. Ή-NMR (400 MHz, DMSO-d6): 7.81 (broad s, exch. with D20, COOH and NH2), 3.79 (t, J = 4.4 Hz, 1H, CH), 3.66 (d, J = 4.8 Hz, 2H, CH2), 3.38 (s, 3H, OMe). I3C-NMR (100 MHz, DMSO-d6): 169.06, 158.29 (q, J = 31.3 Hz, CF3COOH), 1 17.20 (q, J = 297.6 Hz, CF3), 70.1 1 (OCH3), 58.50 (OCH2), 52.80 (CHCOOH). EI-MS: 121 (M + 2), 120 (M + 1), and 88 (M - OCH3).
Example 3:
Preparation of N-acetyl-O-iriethyl-D-serine: Into a 1L, four-necked, RB flask was charged 500 ml of ethyl acetate and 50 g of O-methyl-D-serine trifluoroacetate salt. The reaction mass was cooled to 0-5°C and added acetic anhydride (43.8 g). The reaction mass was stirred at 25°C for 20 h and cooled to 0-5°C. After stirring for lh reaction mass was filtered and washed the wet cake with 50 ml of ethyl acetate. The wet solid was dried at 60°C to get 40g of N-acetyl-O-methyl-D-serine as white crystalline solid.
Example 4:
Preparation of lacosamide: Into a 2L, four-necked RB flask was charged 1250 ml of ethyl acetate and 25 g of N-acetyl-O-methyl-D-serine under nitrogen atmosphere. The reaction mass was cooled to -20°C and added 16.5 g of N-methylmorpholine. Isobutyl chloroformate (22.3 g) was slowly added to the reaction mass. After stirring for 30min benzylamine (17.5 g) was slowly added to the reaction mass and stirred for 30min. Temperature of the reaction mass was raised to 25-30°C and stirred for lh. Reaction mass was quenched with 100 ml of IN HC1 and transferred into a separating funnel. Organic layer was washed with brine and dried over sodium sulphate. Solvent was partially distilled of from the mass under vacuum. The residue was kept under stirring and filtered the solid. The wet solid was recrystallized from ethyl acetate to get 35g of pharma grade lacosamide. Chiral HPLC purity is >99.9% and the related impurities are <0.5%.
Advantages of present invention:
1. Present process uses cheap and readily available raw materials.
2. Present process avoids the usage of phase transfer catalysts in methylation step. 3. Present process utilizes high purity crystalline solids such as compound of fOrmulae-XXXII and XII for making lacosamide.
4. Lacosamide produced by the process of present invention is free of chiral impurity.
5. Present process is shorter, simpler, and free from usage of hazardous reagents. 6. Present process is economically and commercially viable.

Claims

We claim:
1. Improved process for the preparation of lacosamide of formula-I,
Figure imgf000014_0001
which comprises:
(i) reaction of D-serine with Boc anhydride in the presence of a base in aqueous medium at -10 to 30°C to get -Boc derivative of formula-XVI,
Figure imgf000014_0002
XVI
(ii) reaction of N-Boc derivative of formula-XVI with dimethyl sulphate in the presence of a base in aqueous medium at 0-30°C to get the compound of formula- XVII,
Figure imgf000014_0003
XVII
(iii) reaction of compound of formula-XVII with trifluoroacetic acid at 0-60°C to get the novel trifluoroacetate salt of O-methyl-D-serine of formula-XXXII,
Figure imgf000014_0004
XXXII
(iv) acetyl ation of compound of formula-XXXII with acetic anhydride or acetyl chloride to get the compound of formula-XIII,
1
Figure imgf000015_0001
X I I I
(v) amidation of compound of formula-XIII with benzylamine via a carbamate intermediate at -100 to 35°C to get crude lacosamide of formula-I,
Figure imgf000015_0002
(vi) recrystallization of crude lacosamide from a solvent to get pharmaceutically acceptable grade lacosamide.
The process according to claim 1 wherein the base used in step (i) is selected from sodium or potassium hydroxide, carbonate, bicarbonate, etc., preferably sodium or, potassium hydroxide, more preferably sodium hydroxide.
3. The process according to claims 1 and 2 wherein the amount of base used in step (i) is selected from 2-3 equivalents to the amount of D-serine.
4. The process according to claims 1 -3 wherein the base used in step (ii) is selected from sodium or potassium hydroxide, carbonate, bicarbonate, etc., preferably sodium or potassium hydroxide, more preferably sodium hydroxide.
The process according to claims 1-4 wherein the acid used for neutralization of base in step (ii) is selected form organic acid such as acetic, propionic, oxalic, citric acid or a mineral acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, preferably citric acid or sulfuric acid.
2
6. The process according to claims 1-5 wherein the solvent used for extraction of compound of formula-XVII in step (ii) is selected from ethers such as diethyl ether, diisopropyl ether, methyl isobutyl ether, methyl tert-butyl ether, esters such as ethyl acetate, isopropyl acetate, halogenated solvents such as methylene
5 chloride, chloroform, hydrocarbon solvents such as cyclohexane. toluene, preferably ethyl acetate or diisopropyl ether.
7. The process according to claims 1 -6 wherein the mole equivalents of trifluoroacetic acid used in step (iii) is 5 to 20 moles equivalents, preferably 10 mole equivalents. -
10
8. The process according to claims 1-7 wherein the mole equivalents of acylating agent used in step (iv) is 1 to 5 mole equivalents, preferably 2 mole equivalents.
9. The process according to claims 1-8 wherein the acylating agent used in step (iv) Ί5 is acetic anhydride.
10. The process according to claims 1-9 wherein the preferred temperature of reaction in step (v) is -40 to 30°C, more preferably -20 to 30°C.
20 1 1. The process according to claims 1-10 wherein the solvent used in crystallization of lacosamide is selected from ethers such as diethyl ether, diisopropyl ether, methyl isobutyl ether, methyl tert-butyl ether, esters such as ethyl acetate, isopropyl acetate, halogenated solvents such as methylene chloride, chloroform, hydrocarbon solvents such as cyclohexane, toluene, preferably ethyl acetate or
25 diisopropyl ether.
30
3
PCT/IN2011/000082 2010-02-08 2011-02-04 A process for the preparation of lacosamide WO2011095995A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1020127023472A KR20120128667A (en) 2010-02-08 2011-02-04 A process for the preparation of lacosamide
EP11711153.4A EP2534128A1 (en) 2010-02-08 2011-02-04 A process for the preparation of lacosamide
CA2788451A CA2788451A1 (en) 2010-02-08 2011-02-04 A process for the preparation of lacosamide
US13/577,367 US8759582B2 (en) 2010-02-08 2011-02-04 Process for the preparation of lacosamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN314/CHE/2010 2010-02-08
IN314CH2010 2010-02-08

Publications (1)

Publication Number Publication Date
WO2011095995A1 true WO2011095995A1 (en) 2011-08-11

Family

ID=43836601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000082 WO2011095995A1 (en) 2010-02-08 2011-02-04 A process for the preparation of lacosamide

Country Status (5)

Country Link
US (1) US8759582B2 (en)
EP (1) EP2534128A1 (en)
KR (1) KR20120128667A (en)
CA (1) CA2788451A1 (en)
WO (1) WO2011095995A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030654A1 (en) 2011-08-29 2013-03-07 Signa S.A. De C.V. Processes for the preparation of (r)-2-acetamido-n-benzyl-3-methoxypropionamide and intermediates thereof
US8748660B2 (en) 2012-07-09 2014-06-10 Council Of Scientific & Industrial Research Process for the synthesis of antiepileptic drug lacosamide
CN104761465A (en) * 2015-03-18 2015-07-08 四川同晟生物科技有限公司 Preparation method of lacosamide
JP2016535748A (en) * 2013-11-08 2016-11-17 エスティ ファーム カンパニー リミテッド Method for producing lacosamide
EP3144295A1 (en) * 2015-09-18 2017-03-22 Divi's Laboratories Limited Process for the preparation of lacosamide
WO2018060781A1 (en) * 2016-09-28 2018-04-05 Unichem Laboratories Ltd An improved process for the preparation of lacosamide

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6179054B2 (en) * 2013-07-02 2017-08-16 パナソニックＩｐマネジメント株式会社 Bidirectional DC / DC converter, bidirectional power converter
CN114685317A (en) * 2020-12-25 2022-07-01 成都硕德药业有限公司 Preparation method of medicine for treating epilepsy
CN115616118B (en) * 2022-12-19 2023-02-28 北京澳合药物研究院有限公司 High performance liquid chromatography for high performance separation and detection of related substances in D-serine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033861A1 (en) 1996-03-15 1997-09-18 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
WO2006037574A1 (en) 2004-10-02 2006-04-13 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20090143472A1 (en) 2007-12-04 2009-06-04 Mukesh Kumar Madhra Intermediate compounds and their use in preparation of lacosamide
CN101591300A (en) 2009-02-19 2009-12-02 成都伊诺达博医药科技有限公司 The novel method of synthesizing lacosamide

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033861A1 (en) 1996-03-15 1997-09-18 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
WO2006037574A1 (en) 2004-10-02 2006-04-13 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20080027137A1 (en) 2004-10-02 2008-01-31 Schwarz Pharma Ag Synthesis Scheme for Lacosamide
US20090143472A1 (en) 2007-12-04 2009-06-04 Mukesh Kumar Madhra Intermediate compounds and their use in preparation of lacosamide
CN101591300A (en) 2009-02-19 2009-12-02 成都伊诺达博医药科技有限公司 The novel method of synthesizing lacosamide

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALBECK, AMNON ET AL: "Peptidyl Epoxides: Novel Selective Inactivators of Cysteine Proteases", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 5, 1996, pages 3591 - 3596, XP002632558 *
BIOORG. MED. CHEM., vol. 16, 2008, pages 8968 - 8975
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MA, YINLING ET AL: "Synthesis of lacosamide", XP002632556, retrieved from STN Database accession no. 2010:184432 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MING, FANGYONG ET AL: "Process for preparation of lacosamide from BOC-D-serine or Cbz-D-serine", XP002632555, retrieved from STN Database accession no. 2009:1525475 *
J. MED. CHEM., vol. 39, 1996, pages 1907 - 1916
MA, YINLING ET AL: "Synthesis of lacosamide", ZHONGGUO YIYAO GONGYE ZAZHI , 40(9), 641-643 CODEN: ZYGZEA; ISSN: 1001-8255, 2009, XP009145641 *
ORGANIC SYNTHESES, COLL., vol. 7, 1990, pages 70
TETRAHEDRON: ASYMMETRY, vol. 9, 1998, pages 3841 - 3854

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030654A1 (en) 2011-08-29 2013-03-07 Signa S.A. De C.V. Processes for the preparation of (r)-2-acetamido-n-benzyl-3-methoxypropionamide and intermediates thereof
US9133101B2 (en) 2011-08-29 2015-09-15 Signa S.A. De C.V. Processes for the preparation of (R)-2-acetamido-N-benzyl-3-methoxypropionamide and intermediates thereof
US8748660B2 (en) 2012-07-09 2014-06-10 Council Of Scientific & Industrial Research Process for the synthesis of antiepileptic drug lacosamide
JP2016535748A (en) * 2013-11-08 2016-11-17 エスティ ファーム カンパニー リミテッド Method for producing lacosamide
CN104761465A (en) * 2015-03-18 2015-07-08 四川同晟生物科技有限公司 Preparation method of lacosamide
EP3144295A1 (en) * 2015-09-18 2017-03-22 Divi's Laboratories Limited Process for the preparation of lacosamide
CN106543018A (en) * 2015-09-18 2017-03-29 迪比斯实验股份有限公司 The method for preparing scheme for lacosamide
WO2018060781A1 (en) * 2016-09-28 2018-04-05 Unichem Laboratories Ltd An improved process for the preparation of lacosamide
US10414720B2 (en) 2016-09-28 2019-09-17 Unichem Laboratories Ltd. Process for the preparation of lacosamide

Also Published As

Publication number Publication date
CA2788451A1 (en) 2011-08-11
KR20120128667A (en) 2012-11-27
US20130035508A1 (en) 2013-02-07
EP2534128A1 (en) 2012-12-19
US8759582B2 (en) 2014-06-24

Similar Documents

Publication Publication Date Title
US8759582B2 (en) Process for the preparation of lacosamide
US20210009611A1 (en) Benzyl compound
US8907132B2 (en) Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide
ES2895120T3 (en) New diphenylmethane protective agent
JP5803674B2 (en) Benzyl compounds
US10870667B2 (en) Alkyldiphenylmethane protective agent
EP2067765A2 (en) Intermediate compounds and their use in preparation of lacosamide
WO2014016740A2 (en) Improved process for the preparation of pralatrexate
WO2016024284A2 (en) A process for the preparation of mirabegron and its intermediates
WO2013011526A1 (en) Process for preparation of lisdexamphetamine and salts thereof
US8957252B2 (en) Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives
EP3519382A1 (en) An improved process for the preparation of lacosamide
US11498917B2 (en) Process for the preparation of lifitegrast
US20110319649A1 (en) Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide
WO2012117410A1 (en) A process for the preparation of n-[2-[(acetylthio) methyl]-1-oxo-3-phenylpropyl] glycine phenyl methyl ester and intermediates thereof
JP5704763B2 (en) Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivative
JPWO2019123994A1 (en) New alkyldiphenylmethane protective agent
US8664443B2 (en) Process for the preparation of (1S, 3S, 5S)-2-[2(S)-2-amino-2-(3-hydroxy-1-adamantan-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile
WO2014083575A2 (en) Improved process for the preparation of boceprevir intermediate
US9416105B2 (en) Process for preparation of saxagliptin and its hydrochloride salt
EP2855432A1 (en) Process for preparation of (1s, 3s, 5s)-2-[(2s)-2-amino-2-(3-hydroxy-1-adamantyl) acetyl]-2-azabicyclo [3.1.0]hexane-3-carbonitrile
WO2021140480A1 (en) Method for the preparation of aramchol
US6960567B2 (en) Method of producing n-[(2S)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-L-leucyl-L-tert-leucine N-methylamide and intermediate thereof
WO2014155264A1 (en) Process for the preparation of lacosamide using novel intermediates
CA2273286A1 (en) Process for the preparation of nmda antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11711153

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2788451

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011711153

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127023472

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13577367

Country of ref document: US